AU2001293899A1 - Ihnalation particles incorporating a combination of two or more active ingredients - Google Patents

Ihnalation particles incorporating a combination of two or more active ingredients

Info

Publication number
AU2001293899A1
AU2001293899A1 AU2001293899A AU9389901A AU2001293899A1 AU 2001293899 A1 AU2001293899 A1 AU 2001293899A1 AU 2001293899 A AU2001293899 A AU 2001293899A AU 9389901 A AU9389901 A AU 9389901A AU 2001293899 A1 AU2001293899 A1 AU 2001293899A1
Authority
AU
Australia
Prior art keywords
combination
active ingredients
particles
ihnalation
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293899A
Inventor
Petri Ahonen
David Brown
Esko Kauppinen
Esa Muttonen
Wiwik Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8559251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001293899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of AU2001293899A1 publication Critical patent/AU2001293899A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders.
AU2001293899A 2000-10-06 2001-10-05 Ihnalation particles incorporating a combination of two or more active ingredients Abandoned AU2001293899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20002215 2000-10-06
FI20002215A FI20002215A0 (en) 2000-10-06 2000-10-06 Combination Particles
PCT/FI2001/000863 WO2002028377A1 (en) 2000-10-06 2001-10-05 Ihnalation particles incorporating a combination of two or more active ingredients

Publications (1)

Publication Number Publication Date
AU2001293899A1 true AU2001293899A1 (en) 2002-04-15

Family

ID=8559251

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293899A Abandoned AU2001293899A1 (en) 2000-10-06 2001-10-05 Ihnalation particles incorporating a combination of two or more active ingredients

Country Status (9)

Country Link
US (2) US7267813B2 (en)
EP (1) EP1322300B1 (en)
JP (1) JP4316873B2 (en)
AT (1) ATE284680T1 (en)
AU (1) AU2001293899A1 (en)
CA (1) CA2424620A1 (en)
DE (1) DE60107862T2 (en)
FI (1) FI20002215A0 (en)
WO (1) WO2002028377A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20002215A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
FI20002216A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
FI20011386A0 (en) * 2001-06-28 2001-06-28 Orion Corp Inhalation particles
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
EP2359817B1 (en) * 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005051511A1 (en) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation Method for producing fine organic compound particles
CA2581764A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Minicapsule formulations
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
WO2007011989A2 (en) * 2005-07-15 2007-01-25 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
FI20060428L (en) * 2006-05-03 2007-11-04 Esko Kauppinen Surface-modified aerosol particles, method and device for their production and powders and dispersions containing said particles
PL2077830T3 (en) * 2006-10-17 2013-04-30 Lithera Inc Methods, compositions, and formulations for the treatment of thyroid eye disease
US9114071B2 (en) 2007-04-04 2015-08-25 Sigmoid Pharma Limited Oral pharmaceutical composition
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
JP2010527285A (en) 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド Production of multiple mini capsules
EP2073798A2 (en) * 2007-05-01 2009-07-01 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
EP2022798A1 (en) 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides
WO2009079078A1 (en) 2007-12-14 2009-06-25 Labogroup S.A.S. Delivering aerosolizable food products
PL2413902T3 (en) * 2009-03-18 2020-01-31 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
ES2649112T3 (en) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composition comprising drops of oil
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
DK2435024T3 (en) 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
WO2011018504A2 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
KR20120113267A (en) * 2010-01-15 2012-10-12 리쎄라 인코오포레이티드 Lyophilized cake formulations
CN102416179B (en) 2010-09-28 2014-05-07 益得生物科技股份有限公司 Inhaled compound composition for asthma
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JOP20120023B1 (en) 2011-02-04 2022-03-14 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
LT3527196T (en) * 2012-01-25 2022-11-25 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
ES2814336T3 (en) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Aggregate particles
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
AU2013388034B2 (en) 2013-04-30 2019-08-15 Vectura Inc. Dry powder formulations and methods of use
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP4119131A1 (en) 2014-02-20 2023-01-18 Otitopic Inc. Dry powder formulations for inhalation
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
BR112017009510A2 (en) 2014-11-07 2017-12-19 Sigmoid Pharma Ltd compositions comprising cyclosporine
AU2017215189A1 (en) * 2016-02-01 2018-08-02 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
BE1027612B1 (en) * 2019-09-10 2021-05-03 Aquilon Pharmaceuticals GOLF BALL-SHAPED MICROPARTICLES FOR USE IN THE TREATMENT AND PREVENTION OF PULMONARY DISEASES

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
FR2624505A1 (en) * 1987-12-11 1989-06-16 Rhone Poulenc Chimie STABILIZED ZIRCONIA, PROCESS FOR PREPARING THE SAME AND APPLICATION THEREOF IN CERAMIC COMPOSITIONS
US5096629A (en) * 1988-08-29 1992-03-17 501 Nippon Fine Chemical Co., Ltd. Method for preparing lipid powder for use in preparing liposomes and method for preparing liposomes
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Pharmaceutical compositions comprising salmeterol and fluticasone propionate
CA2024872C (en) 1989-09-08 2002-07-09 James Barry Douglas Palmer Medicaments
SE9302777D0 (en) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
JP3342484B2 (en) * 1991-12-18 2002-11-11 アストラ・アクチエボラーグ New formulation
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6051257A (en) * 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
HU226671B1 (en) 1997-03-20 2009-06-29 Schering Corp Preparation of powder agglomerates
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
IT1309592B1 (en) * 1999-03-05 2002-01-24 Chiesi Farma Spa VEHICLE PARTICLES MODIFIED FOR USE IN THE PREPARATION OF PHARMACEUTICAL FORMULATIONS IN THE FORM OF POLYMERS FOR INHALATION AND
FI20002217A (en) 1999-12-30 2001-07-01 Orion Yhtymae Oyj inhalation particles
FI20002215A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination Particles
FI20002216A0 (en) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy

Also Published As

Publication number Publication date
CA2424620A1 (en) 2002-04-11
FI20002215A0 (en) 2000-10-06
DE60107862T2 (en) 2005-12-15
JP2004510731A (en) 2004-04-08
US20040028619A1 (en) 2004-02-12
DE60107862D1 (en) 2005-01-20
EP1322300A1 (en) 2003-07-02
ATE284680T1 (en) 2005-01-15
JP4316873B2 (en) 2009-08-19
EP1322300B1 (en) 2004-12-15
US7267813B2 (en) 2007-09-11
US20080254127A1 (en) 2008-10-16
WO2002028377A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
AU2001293899A1 (en) Ihnalation particles incorporating a combination of two or more active ingredients
AU2001293900A1 (en) Combination particles for the treatment of asthma
JO2430B1 (en) Pharmaceuticall Formulations for Dry Powder Inhalers in the form of Hard- Pellets
CA2406119A1 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
BR9915095A (en) Pharmaceutical composition administered in aerosol
WO2002043702A3 (en) Pharmaceutical compositions for inhalation
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
CA2322045A1 (en) Aerosolized active agent delivery
WO2000025746A3 (en) A process for the preparation of suspensions of drug particles for inhalation delivery
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
CA2412561A1 (en) Highly efficient delivery of a large therapeutic mass aerosol
IL219785A (en) Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
CA2395653A1 (en) New inhalable powder containing tiotropium
CA2125665A1 (en) Medicaments
CA2290538A1 (en) Composition comprising finely divided, crystalline particles of budesonide
BRPI0408047A (en) medicine containing a highly potent long-acting beta2 agonist in combination with other active ingredients
AU2001236207A1 (en) Powder formulation
JO3102B1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
AU2002316820A1 (en) Powder inhaler formulations
CA2461517A1 (en) Nicotine formulations comprising cocoa and use thereof
AU2003225915A1 (en) Formoterol and mometasone aerosol formulations
TNSN05048A1 (en) Inhalation compositions with high drug ratios
WO2003079885A3 (en) Inhalable sustained therapeutic formulations
HUP0104478A2 (en) Milling process for the production of finely milled medicinal substances